Table 2: The occurrence of adverse cardiovascular events in 4-month and 4-year follow-ups of patients treated with PCI in the acute phase of myocardial infarction with persistent ST segment elevation depending on glucose level on admission.
|
Glc on admission |
<7.8 mmol/L |
|
≥7.8 mmol/L |
|
<7.8 mmol/L |
|
≥7.8 mmol/L |
|
|
MACE |
after 4 months |
p value |
after 4 years |
p value |
||||
|
In Total |
3 (6.9%) |
vs |
9 (24.3%) |
0.0633 |
11 (23.9%) |
vs |
23 (50%) |
0.01 |
|
Death |
1 (2.1%) |
vs |
1 (2.1%) |
|
2 (4.3%) |
vs |
4 (8.7%) |
|
|
Cardiac death |
0 |
vs |
1 (2.1%) |
|
1 (2.1%) |
vs |
2 (4.3%) |
|
|
Myocardial infarction |
0 |
vs |
2 (4.3%) |
|
3 (6.5%) |
vs |
8 (7.4%) |
|
|
PCI/CABG |
1 (2.1%) |
vs |
4 (8.7%) |
|
4 (8.7%) |
vs |
9 (9.6%) |
|
|
Hospitalisation due to CHF |
1 (2.1%) |
vs |
2 (4.3%) |
|
1 (2.1%) |
vs |
2 (4.3%) |
|
|
Stroke |
|
0 |
|
|
1 (2.1%) |
vs |
0 |
|